Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Urologic Neoplasms × Afatinib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 58 Neoplasms 21 Squamous Cell Carcinoma of Head and Neck 12 Breast Neoplasms 11 Lung Neoplasms 10 Head and Neck Neoplasms 10 Neoplasm Metastasis 8 Carcinoma, Squamous Cell 6 Esophageal Squamous Cell Carcinoma 5 Stomach Neoplasms 4 Pancreatic Neoplasms 4 Prostatic Neoplasms 3 Glioblastoma 3 Esophageal Neoplasms 3 Colorectal Neoplasms 3 Adenocarcinoma 3 Solid Tumors 2 Non-small-cell Lung Cancer With Somatic EGFR Mutations 2 NSCLC 2 Multiple Myeloma 2 Brain Neoplasms 2 Adenocarcinoma of Lung 2 Urologic Neoplasms 1 Urinary Bladder Neoplasms 1 Urethral Neoplasms 1 Ureteral Neoplasms 1 Triple Negative Breast Neoplasms 1 Thrombocytosis 1 Thoracic Neoplasms 1 Squamous Non-small Cell Lung Cancer 1

Interventions

Gemcitabine 7 pembrolizumab 4 atezolizumab 3 Trastuzumab 3 Sunitinib 3 Carboplatin 3 enfortumab vedotin 2 dodecyl maltoside 2 cabozantinib 2 Water 2 Standard of Care 2 Pemetrexed 2 Paclitaxel 2 Cisplatin 2 Cetuximab 2 Bevacizumab 2 vinflunine 1 valrubicin 1 tislelizumab 1 testosterone 17 beta-cypionate 1 temsirolimus 1 poly ICLC 1 niraparib 1 montanide ISA 51 1 lenvatinib 1 flt3 ligand protein 1 delta 24-sterol reductase 1 daratumumab 1 avelumab 1 abemaciclib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT02780687 2020-11-18

LUX-Bladder 1

Boehringer Ingelheim

Phase 2 Completed

42 enrolled 16 charts

Urologic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡